Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Hydrochloride Liposome Injection in Relapsed/Refractory or Unfit AML (Phase I/II, China)
CTR20220799Phase 2Terminated
- Sponsor
- CSPC Pharmaceutical Group
- Start
- Apr 2022
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone hydrochloride liposome in acute myeloid leukemia (AML), sponsored by CSPC Pharmaceutical Group. Primary endpoints: Dose-limiting toxicities (DLTs) in dose-escalation phase and Complete remission (CR) rate in dose-expansion phase. Started Apr 2022; status: terminated.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20220799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220799.